Released in late 2021 (approximate date based on case numbering sequences), Shoplyfter Amber Summer Case No 7906272 arrived at a peak moment for the series. It followed several lackluster entries that relied too heavily on aggressive dialogue without emotional payoff. Summer's entry reset the bar.
For collectors and aficionados, this case number is often the "gateway" video they show to newcomers. Why? Because it encapsulates the Shoplyfter ethos perfectly: high stakes, believable characters, and a resolution that feels earned within the logic of the world.
Amber Summer herself has cited this scene in interviews (on niche podcast circuits) as her personal favorite, noting that the director allowed significant improvisation in the second act. "The script said 'Jenna gets scared,'" she recalled. "I decided that Jenna would get angry before she got scared. That shift made the case special." shoplyfter amber summer case no 7906272 top
| Date | Event | |------|-------| | June 15 2023 | Complaint filed (Case No. 7906272‑T‑OP). | | July 8 2023 | Defendants filed motions to dismiss (including a Section 230 motion). | | Oct 2 2023 | Plaintiffs filed Amended Complaint, adding specific allegations about the chemical composition of the cooling pad (polyethylene glycol + proprietary fragrance). | | Jan 14 2024 | Motion to Dismiss heard; Judge Miriam L. Ortiz (E.D. Cal.) issued a partial‑dismissal order. The court dismissed the Section 230 claim (finding it inapplicable to product‑safety claims) but allowed the warranty, negligence, and FTC claims to proceed. | | Feb 2024 – Aug 2024 | Discovery phase, including: (i) depositions of Shoplyfter’s compliance officers, (ii) production of internal testing reports from CoolTech Labs, (iii) third‑party expert analysis of the chemical irritants. | | Sept 2024 | Plaintiffs filed a motion for class certification. | | Nov 2024 | Court granted class certification under Rule 23(b)(1) and (b)(3), finding common questions of law (the veracity of the “FDA‑cleared” claim) and a common injury pattern. | | Dec 2024 – March 2025 | Summary‑judgment motions. Shoplyfter moved for summary judgment on the warranty claim; plaintiffs opposed, arguing materiality of the “FDA‑cleared” language. | | April 30 2025 | Summary‑judgment order: The court denied Shoplyfter’s motion on the warranty claim (finding that the “FDA‑cleared” statement was likely false and material) but granted summary judgment on the negligence claim against Amber Summer LLC (insufficient evidence of a duty beyond product design). | | June 2025 | Settlement conference; parties entered mediation. | | Oct 2025 | Settlement reached: Shoplyfter and CoolTech Labs agreed to a $9.8 million settlement (including $4 million for class members, $2 million for attorney fees, and $3.8 million for future product‑safety monitoring). The settlement required the defendants to: (i) cease the “FDA‑cleared” language, (ii) implement a third‑party certification process, and (iii) fund a consumer‑education fund. | | Jan 2026 | Court entered final judgment confirming the settlement and entered an order of permanent injunction prohibiting the misrepresentations. |
The court applied the Gillespie v. United Airlines (1998) standard. Common questions of law (the validity of the FDA claim) and common factual issues (the nature of injuries) were present. The numerosity and typicality requirements were met, and the superiority of a class action over individual lawsuits was evident given the uniformity of the product and the relatively modest damages per plaintiff. Released in late 2021 (approximate date based on
Law review articles (e.g., J. Tech. L. & Pol’y 2025) have cited the case as “Shoplyfter v. Summer, 7906272‑T‑OP (E.D. Cal. 2025)", noting its contribution to the evolving “mixed‑content” doctrine—a framework to assess when a platform’s involvement crosses the threshold from passive host to active publisher.
The FTC’s “misleading claims” standard requires that the representation be material and likely to mislead a reasonable consumer. The court found that the “FDA‑cleared” language satisfied both prongs, aligning the FTC claim with the warranty analysis. The court applied the Gillespie v
Although the summary‑judgment phase focused on warranty, the court’s opinion noted that the chemical analysis performed by an independent toxicology lab identified propylene glycol at concentrations exceeding the Consumer Product Safety Commission (CPSC) limits for skin contact. This finding supported the plaintiffs’ claim that the vest was defectively designed. However, the parties resolved the matter through settlement before a full trial on strict liability could proceed.